Qiang Mu

Dr. Qiang Mu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Advanced Composites and Hybrid Materials
Verified
Journal Article
Closed access
PDF file
HZHanyu Zhang
Hanyu Zhang
JXJing Xia
Jing Xia
LXLingling Xie
Lingling Xie
MHMeng Hao
Meng Hao
WLWenlong Liang
Wenlong Liang
QMQiang Mu
Qiang Mu

11 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SWSizhang Wang
Sizhang Wang
XWXiaoyan Wang
Xiaoyan Wang
JXJing Xia
Jing Xia
QMQiang Mu
Qiang Mu
Over the past several decades, there has been a significant increase in the number of breast cancer patients. Among the four subtypes of breast cancer, Her2-positive breast cancer is one of the most aggressive breast cancers. In this study, we screened the differentially expressed genes from The Cancer Genome Atlas-Breast cancer database and analyzed the relationship between immune cell infiltration and differentially expressed genes using weighted gene co-expression network analysis. By constructing a module–trait relationships heatmap, the red module, which had the highest correlation value with M1 macrophages, was selected. Twenty hub genes were selected based on a protein–protein interaction network. Then, four overlapping M1 macrophage infiltration-related genes (M1 MIRGs), namely CCDC69, PPP1R16B, IL21R, and FOXP3, were obtained using five machine-learning algorithms. Subsequently, nomogram models were constructed to predict the incidence of Her2-positive breast cancer patients. The outer datasets and receiver operating characteristic curve analysis were used to validate the accuracy of the four M1 MIRGs and nomogram models. The average value of the area under the curve for the nomogram models was higher than 0.75 in both the training and testing sets. After that, survival analysis showed that higher expression of CCDC69, PPP1R16B, and IL21R were associated with overall survival of Her2-positive breast cancer patients. The expression of CCDC69 and PPP1R16B could lead to more benefits than the expression of IL21R and FOXP3 for immunotherapy. Lastly, we conducted immunohistochemistry staining to validate the aforementioned results. In conclusion, we found four M1 MIRGs that may be helpful for the diagnosis, prognosis, and immunotherapy of Her2-positive breast cancer.

19 November 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
KFKun Fang
Kun Fang
CWCuiping Wang
Cuiping Wang
ZLZhenfeng Li
Zhenfeng Li
LWLi Wang
Li Wang
XWXintong Wang
Xintong Wang
QMQiang Mu
Qiang Mu
Introduction: This study aimed to characterize time-dependent metabolic alterations and identify metabolites associated with treatment response in HER2-negative breast cancer patients undergoing neoadjuvant chemotherapy (NAC) with the TEC regimen (docetaxel, epirubicin, and cyclophosphamide). Methods: A total of 60 plasma samples were collected from 20 patients at three time points: baseline (T1), after three cycles of NAC (T2), and before surgery (T3). Pathological assessment classified patients into three response groups: pathologic complete response (pCR, n = 5), pathologic partial response (pPR, n = 7), and pathologic stable disease (pSD, n = 8). Results: After three cycles of NAC, a greater decrease in glycochenodeoxycholate was associated with poorer treatment response, whereas a larger reduction in LysoPC(18:1) correlated with better response. Following six cycles, elevated epinephrine levels were positively associated with therapeutic efficacy, while increased cysteine levels were linked to unfavorable outcomes. Ursodeoxycholic acid showed an upward trend in pCR patients but declined in pPR and pSD groups. Combined analysis of ursodeoxycholic acid and cysteine improved the predictive performance for treatment response. Discussion: These findings reveal dynamic metabolic reprogramming during NAC and suggest that ursodeoxycholic acid and cysteine may serve as potential predictive biomarkers of therapeutic efficacy in HER2-negative breast cancer patients treated with the TEC regimen.

18 September 2026 in Translational Oncology
Verified
Journal Article
Open access
SWSizhang Wang
Sizhang Wang
HWHua Qi Wang
Hua Qi Wang
HZHui Zhao
Hui Zhao
RZRuixia Zhao
Ruixia Zhao
PZPeng Zhao
Peng Zhao
QMQiang Mu
Qiang Mu
M2-like tumor-associated macrophages (TAMs), recognized as a significant risk factor in tumor progression, play a crucial role in the tumor microenvironment. While Sialic acid binding Ig like Lectin 15 (Siglec-15), an well-characterized immune-checkpoint inhibitor, has been demonstrated to impact immunotherapy response and tumor progression, its role in TMAs-mediated tumor progression remains largely unclear. In this study, we demonstrated that the high expression of Siglec-15 in triple-negative breast cancer (TNBC) acts as a pivotal driver of the interaction between tumor cells and macrophages. TNBC cells with overexpressed Siglec-15 can induce the polarization of macrophages into CC chemokine ligand 18 (CCL18)+ M2 macrophages and recruit macrophages. Furthermore, CCL18⁺ M2 TAMs can directly facilitate the malignant behaviors of TNBC cells. Mechanistically, they secrete CCL18, which promotes the expression of Siglec-15 via the phosphorylation of signal transducer and activator of transcription 3 (STAT3), thereby indirectly accelerating tumor progression. Molecular biochemical assays, including RNA sequencing on TNBC cells with overexpressed Siglec-15 and capillary reverse-phase liquid chromatography (LC)-tandem mass spectrometry (MS/MS) of the cell supernatant, demonstrated Siglec-15 upregulated the expression of Decoy receptor 3 (DcR3) in macrophages through Nuclear factor-kappa B (NF-κB) pathway. In summary, this study reveals a novel Siglec-15-mediated positive feed-forward loop between TNBC cells and macrophages, which relies on the NF-κB/DcR3/CCL18/STAT3 signaling axis to facilitate TNBC progression..